Medtech Has Hope For A Solid Recovery Later In 2021
Medtech Is Still An Attractive Market Says Jefferies Healthcare
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.